To amend section 3902.50 and to enact sections 5.22108, 3902.65, and 5164.094 of the Revised Code to require health plan issuers and the Medicaid program to cover treatments and services related to Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome.
HB831 would require Ohio health benefit plans and the Medicaid program to cover screening, diagnosis, and treatment for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). The bill also designates October 9 as “PANDAS and PANS Awareness Day.”
For private health plans, the bill would mandate coverage for comprehensive diagnostic evaluation, symptomatic relief, laboratory and imaging services, psychiatric and behavioral services, immunomodulatory therapies such as immunoglobulin, corticosteroids, plasmapheresis, and rituximab or similar products, antimicrobial treatment, and therapeutic care from speech, occupational, and physical therapists. The Medicaid program would be required to provide similar coverage. The bill further prohibits step therapy and prior authorization for the required services and bars insurers and Medicaid from conditioning coverage on a patient meeting a severity threshold or having a specified immunodeficiency status.
HB831 would add a new insurance coverage mandate to Ohio law and create a parallel Medicaid coverage requirement for PANDAS and PANS. It amends the state’s health insurance coverage statutes and enacts new sections governing both private health plan issuers and Medicaid, while also adding an awareness-day designation to the state calendar. The bill would affect insurers, managed care plans, Medicaid administrators, health care practitioners, and families seeking treatment for these conditions by expanding covered services and limiting utilization-management tools.
The bill appears to be introduced in a supportive posture, with a clear sponsor and cosponsor and no recorded committee testimony or votes in the available materials. Because there are no transcripts or vote tallies, the overall sentiment can only be inferred from the bill’s purpose: it reflects a pro-coverage, pro-access approach for a specific pediatric condition. The absence of recorded opposition or amendments in the provided context suggests the measure had not yet generated formal public debate at the time of introduction.
The main points of potential contention are the breadth and specificity of the mandated treatments, especially the inclusion of immunomodulatory therapies such as immunoglobulin, plasmapheresis, and rituximab, which can be costly and medically debated. Another likely issue is the prohibition on prior authorization and step therapy, which limits insurer and Medicaid cost-control and medical-management tools. The bill also removes coverage conditions tied to symptom severity or immunodeficiency status, which may concern payers who prefer narrower medical-necessity standards. Finally, the provision making the mandate inoperative if the state would have to defray costs under federal law reflects concern about potential state fiscal exposure.